Celcuity's REVTORPYK Gets FDA Approval for HR+/HER2- Breast Cancer
() -- Celcuity (CELC) said Tuesday the US Food and Drugs Administration approved REVTORPYK for treating patients with hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation, a specific genetic alteration, following progression after endocrine therapy. The approva